Key Highlights

  • Basel Medical Group (NASDAQ:BMGL) was priced at USD 0.5217 during the November 12, 2026 session, a 23.73% slide, with roughly 1.06 million shares changing hands and a Market Value close to USD 7.09 million.
  • October's raise sold 6,000,000 units at USD 1.33 apiece, producing about USD 7.98 million before costs and expanding shares outstanding from roughly 1.58 million to about 7.58 million.
  • Every unit contained a Warrant that can be exercised for stock without a cash payment, creating up to 6,000,000 more shares that could reach the market.
  • No company announcement appeared between November 10 and 12, so the latest decline has no confirmed trigger.

Dilution Is Driving the Share Price

Basel Medical Group (NASDAQ:BMGL) is a Singapore healthcare provider covering orthopaedic and trauma care, sports medicine, spine and neurosurgical treatment, health screening, mental health, women's health and general practice. On October 8, 2026 the company priced a registered direct sale of 6,000,000 units at USD 1.33 apiece, with each unit pairing one share and one common warrant. The deal closed October 9, bringing in about USD 7.98 million gross and roughly USD 7.28 million net. The share count nearly quintupled, moving from about 1.58 million to about 7.58 million. The warrants allow zero-cash exercise into up to 6,000,000 additional shares, so new stock may arrive without any further cash flowing to the company. The shares now trade far below the offering price. Since no announcement surfaced for November 10 to 12, any link between continued selling and this overhang is an interpretation rather than a confirmed cause. Holders who owned stock before the transaction have already taken on a much larger share base.

Listing Pressure Through 2026

Throughout 2026 the company has been dealing with Nasdaq rules. A bid price deficiency letter arrived in January. A 1-for-12 reverse split, effective June 22, trimmed the share total from 18,785,750 to approximately 1,565,480. Minimum bid compliance was restored in July, and a periodic filing shortfall was resolved in March after an amended Annual Report was filed. At USD 0.5217 the stock is again beneath USD 1.00, and a new deficiency letter could follow should the price remain under that level for 30 consecutive Business days. October lock-up agreements prevent the company from issuing shares and insiders from selling for 180 days, yet warrant holders remain free to exercise and sell. Every one of these developments has complicated the task of valuing the business.

Financial Picture and Next Steps

Trailing Revenue is about SGD 11.46 million against a net loss near SGD 7.81 million, a reminder that the company still loses money at its current scale. The screen lists trailing diluted losses of USD 0.37 per share, a 92.79% gain that partly comes from the larger share base. The October proceeds bolster the Balance Sheet and might support clinic expansion or Supply chain activity in Asia-Pacific. Key items to track include the speed of warrant exercises, any Nasdaq correspondence, interim numbers and how the fresh Capital is allocated. While the warrant overhang persists, rallies may keep running into sales from holders who convert warrants into shares. A transparent plan for the proceeds would show whether the dilution is funding meaningful growth. Demand for private specialist care in Singapore provides steady support, though management must demonstrate that the added funds lead to bigger patient volumes and smaller losses.

Where Things Stand

Basel Medical Group (NASDAQ:BMGL) declined 23.73% to USD 0.5217 on November 12, 2026, well below the USD 1.33 unit price from its October raise. No fresh announcement surfaced, but zero-cash warrants on up to 6,000,000 shares and a sub-dollar share price keep dilution and listing risk in the spotlight.